Clinical Studies

Clinical research is very important because it is one of the best ways to improve patient care. Currently, hundreds of studies are taking place throughout Lurie Children's, including at the research institute, that involve many of our doctors, nurses, clinical research professionals, scientists and technicians.

Search below for a clinical study, or to see a more comprehensive listing of the clinical studies taking place at Lurie Children's, please use our link to the website.

You can learn more about the clinical research process on our guide to clinical research for parents and children.

Filter by:


Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH) ID: NCT02913612

Describe the efficacy of 0.25% and 0.5% topical timolol maleate GFS as assessed through IH changes in color. Secondary: Describe the safety and PK of topical timolol maleate GFS for treatment of IH.

Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease ID: NCT 02596997

Provide patients with serious AdV infection or disease access to treatment with BCV

BIOPIC: Fungal Biomakers for Diagnosis and Response to Therapy for Pediatric Candidemia ID: NCT 02220790

This study will create an international multi-center cohort of children with new clinical concern for infecton while in the hospital.  Sites used are part of the International Pediatric Fungal Network (  The study plans to prospectively enroll pediatric patients at high-risk of developing invasve candidiasis over a four year...

Evaluating the Infectivity, Safety, and Immunogenicity of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age ID: NCT03227029

The purpose of this study is to evaluate the infectivity, safety, and immunogenicity of the recombinant live-attenuated respiratory syncytial virus (RSV) vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 or placebo when delivered as nose drops to RSV-seronegative infants 6 to 24 months of age. This study is a companion study to CIR 321.

Safety/Effectiveness Study of Cysteamine Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis ID: NCT01744782

This is a long-term, open-label study of the safety, tolerability and effectiveness of RP103 in cystinosis patients who are naïve to any form of cysteamine treatment. Subjects will receive RP103 treatment for at least 12 months and will continue to participate in the study and receive RP103, until it is available through the appropriate marketing...